SCHEMBL5401433

SCHEMBL5401433

CC(C)Cn1c(CC2CCNCC2)nc2c(N)nc(N)nc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 9/20 0.40
TLR8 Q9NR97 5/20 0.40
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
KCNH2 Q12809 2/20 0.34
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
CDK2 P24941 2/20 0.32
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
CCNE1 P24864 1/20 0.32
PTPN1 P18031 1/20 0.30
CHEK1 O14757 1/20 0.30
CCNA2 P20248 1/20 0.30
CCNA1 P78396 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199449 0.68 PDE8B (0.40) TLR7TLR8ADORA3ADORA2AADORA2B
SCHEMBL6849155 0.67 ADORA3 (0.34) TLR7ADORA3ADORA2AADORA2BADORA1
SCHEMBL6849150 0.67 ADORA3 (0.34) TLR7ADORA3ADORA2AADORA2BADORA1
SCHEMBL2199421 0.67 ADORA2A (0.41) TLR7TLR8ADORA3ADORA2AADORA2B
SCHEMBL5392972 0.67 PIK3CA (0.35) TLR7ADORA3ADORA2AADORA2BADORA1
SCHEMBL5396347 0.65 TLR7 (0.40) TLR7ADORA3ADORA2AADORA2BADORA1
SCHEMBL5438145 0.64 TLR7 (0.44) TLR7TLR8ADORA2AKCNH2PDE4D
SCHEMBL5401999 0.64 ADORA2A (0.39) TLR7ADORA2AADORA2BADORA1CDK2
SCHEMBL15940884 0.64 CACNA1H (0.43) PTPN1
SCHEMBL5398282 0.63 ADORA2A (0.43) TLR7ADORA3ADORA2AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238700-B2 A2B adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-07-03 US disclosed
EP-1401837-B1 PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2005-10-19 EP disclosed
US-20040209899-A1 A2B adenosine receptor antagonists PALLE VENKATA (IN) 2004-10-21 US disclosed
US-6770651-B2 THERAPY FOR ASTHMA, DIARRHEA PALLE VENKATA (US) 2004-08-03 US disclosed
EP-1401837-A1 PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2004-03-31 EP disclosed
US-20030064999-A1 A2B adenosine receptor antagonists PALLE VENKATA (US) 2003-04-03 US disclosed
WO-2003006465-A1 PARTIAL AND FULL AGONIST OF A ADENOSINE RECEPTORS CV THERAPEUTICS, INC. (US) 2003-01-23 WO disclosed
WO-2003002566-A1 PURINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064999-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA1 TLR7 1635/4885TLR8 1348/4885ADORA3 4/4885
US-20040209899-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA1 TLR7 854/4885TLR8 1207/4885ADORA3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.